Breaking News

Financial Report: Baxter 3Q11

BioScience revenues up 9%

Baxter 3Q11

3Q Revenues: $3.5 billion (+8%)

3Q Earnings: $576.0 million (+10%)

YTD Revenues: $10.3 billion (+10%)

YTD Earnings: $1.8 billion (+77%)

Comments: BioScience revenues in the quarter were $1.5 billion (+9%), boosted by Gammagard Liquid, certain plasma-based therapeutics, and vaccines. Medical Products sales were $2.0 billion (+7%). 1Q10 included a charge totaling $588 million related to the recall of COLLEAGUE infusion pumps and 3Q10 included an impairment charge of $112 million associated with the company’s divestiture of its U.S. generic injectables business.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters